Protalix Highlights Positive EMA Opinion on Elfabrio Dosing

Protalix ( (PLX) ) just unveiled an announcement.

On February 11, 2026, Protalix BioTherapeutics posted an updated corporate presentation outlining recent clinical and regulatory developments, most notably a positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use supporting a 2 mg/kg every-four-weeks dosing regimen of Elfabrio for stable adult Fabry patients in the European Union. If confirmed by an expected European Commission decision by the end of March 2026, Elfabrio would become the first and only enzyme replacement therapy in the EU offering an every-four-week option, a change backed by BRIGHT study data and long-term extension results showing maintained clinical and renal outcomes while halving infusion frequency.

The proposed extended dosing schedule directly targets one of Fabry disease’s key unmet needs by lowering treatment burden and potentially improving adherence and persistence, which could strengthen Elfabrio’s competitive profile and support market share gains in Europe. The company also stands to benefit financially through an anticipated $25 million regulatory milestone payment from partner Chiesi upon EC approval, reinforcing the strategic and commercial significance of this regulatory milestone for stakeholders.

The most recent analyst rating on (PLX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Protalix stock, see the PLX Stock Forecast page.

Spark’s Take on PLX Stock

According to Spark, TipRanks’ AI Analyst, PLX is a Neutral.

The score is driven primarily by improved profitability and a healthier balance sheet, offset by deteriorating TTM cash flow and shrinking recent revenue. Technicals are supportive but overbought, while valuation is a headwind given the high P/E and no dividend. Earnings-call updates and recent regulatory news are net positive but do not fully offset the cash-flow and growth concerns.

To see Spark’s full report on PLX stock, click here.

More about Protalix

Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing enzyme replacement therapies and other protein products for rare diseases. Its marketed portfolio includes Elfabrio, approved in the U.S., European Union and additional markets, and Elelyso, approved in 23 markets through partnerships with Pfizer and Brazil’s Fiocruz, underscoring a strategy centered on global rare-disease franchises.

The company leverages long-standing operational expertise and strategic alliances with major pharmaceutical partners, including Chiesi Global Rare Diseases for Elfabrio, to advance a growing pipeline. Management highlights a three-year goal of progressing five to seven rare-disease programs from discovery to the clinic, supported by an experienced leadership team and an accomplished board with deep R&D, clinical, commercial and business development credentials.

Average Trading Volume: 901,555

Technical Sentiment Signal: Buy

Current Market Cap: $225.2M

See more data about PLX stock on TipRanks’ Stock Analysis page.